Alkem Laboratories CFO Nitin Agrawal resigns effective Sep 30, 2026
- Alkem Laboratories CFO Nitin Agrawal resigned to pursue new opportunities
- Cessation from Senior Management Personnel role effective September 30, 2026
- Resignation letter dated July 30, 2026, cited personal growth alignment
- Agrawal oversaw key acquisitions including Adroit, Bombay Ortho, and Occlutech
*this image is generated using AI for illustrative purposes only.
Alkem Laboratories has announced the resignation of Chief Financial Officer Nitin Agrawal, marking a significant leadership change at the pharmaceutical firm. Agrawal will cease to hold the position of Senior Management Personnel effective from September 30, 2026.
Leadership change at Alkem Laboratories
The departure was disclosed under Regulation 30(2) of the SEBI LODR Regulations. Agrawal tendered his resignation on July 30, 2026, citing a desire to pursue new professional opportunities that align more closely with his long-term professional and personal growth.
In his resignation letter addressed to the Chairman, Agrawal expressed gratitude for the opportunity to serve the company. He highlighted several strategic mandates he supported during his tenure, including building the MedTech business from the ground up, the acquisition of Adroit, the creation of Alkem Wellness, and the formation of the Saudi joint venture.
Strategic contributions and handover
Agrawal also noted his involvement in the acquisition of Bombay Ortho and Occlutech, as well as operational improvements such as the liquidation of idle assets like the Indore SEZ plant. He confirmed his commitment to ensuring a seamless handover of all ongoing strategic initiatives before his final exit date.
| Event Detail | Information |
|---|---|
| Company | Alkem Laboratories |
| Resigning Officer | Nitin Agrawal |
| Role | Chief Financial Officer |
| Reason | New professional opportunities |
| Effective Date | September 30, 2026 |
No further details regarding a successor have been provided in the available information.
Historical Stock Returns for Alkem Laboratories
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.21% | +2.38% | -1.89% | +2.98% | -4.45% | +33.68% |
Who will be appointed as the successor CFO, and what is their background in medtech or international joint ventures?
How might the leadership transition impact the execution timeline of the Saudi joint venture and Alkem Wellness initiatives?
Will the upcoming change in financial leadership affect Alkem Laboratories' credit ratings or investor confidence in the near term?
15
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
